First-in-Human trial tests custom cancer vaccine
NCT ID NCT01209871
Summary
This early-stage study is testing a new, personalized DNA vaccine designed to teach the body's immune system to recognize and attack lymphoma cells. It aims to find the safest dose and see if the vaccine triggers an immune response in patients with early, symptom-free disease. The vaccine is made from the patient's own cancer cells and is given as three injections over eight weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.